论文部分内容阅读
获得性T细胞治疗是一种移植治疗手段,通过对自体T细胞进行体外激活和扩增,然后重新输入病人体内,并辅以合适的生长因子,促使其在体内发挥杀伤肿瘤细胞的作用。利用自体肿瘤浸润淋巴细胞的获得性细胞移植,已经成为对转移性黑色素瘤病人最有效的治疗方法,它能够在大约50%的黑色素患者体内抑制肿瘤。而在细胞移植前对宿主进行免疫清除可明显提高效应细胞对肿瘤的杀伤作用。通过基因修饰淋巴细胞使其靶向肿瘤细胞,能够进一步增强输入细胞的功能,从而抑制肿瘤生长。
Acquired T cell therapy is a kind of transplantation therapy, which can activate and expand autologous T cells in vitro and then re-enter the patient’s body, supplemented with appropriate growth factors to promote its role in killing tumor cells in vivo. Acquired cell transplantation using autologous tumor-infiltrating lymphocytes has become the most effective treatment for metastatic melanoma patients, which can suppress tumors in about 50% of melanoma patients. However, immunosurveillance of the host before cell transplantation can significantly increase the killing effect of the effector cells on the tumor. By genetically modifying lymphocytes to target tumor cells, the function of the input cells can be further enhanced, thereby inhibiting tumor growth.